News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
New and experimental hepatitis C treatment
University launches iphone app for hepatitis treatment

The University of Liverpool has launched an iphone app, HEP i-chart, that provides Hepatitis C patients with quick and easy access to the latest information about drug interactions.

Published
22 November 2011
From
Eurekalert Medicine & Health
Pharmaceutical industry
HIV Drug Giant Gilead Acquires Pharmasset, a Hep C Drug Development Leader

To the tune of $11 billion, Gilead Sciences—a leader in HIV drug development and sales—has acquired one of the most talked-about pharmaceutical companies in the field of hepatitis C virus (HCV) treatment research: Pharmasset, Inc., based in Princeton, New Jersey.

Published
21 November 2011
From
AIDSMeds.com
New and experimental hepatitis C treatment
Transgene’s Therapeutic HCV Vaccine TG4040 Combined with Commonly Used Treatment Achieves Substantial Viral Suppression in Randomized Phase II trial

The HCVac study is a three-arm (one control and two experimental arms with different schemes of administration) randomized Phase II trial evaluating the safety and efficacy of TG4040, a therapeutic vaccine, in combination with ribavirin (“RBV”) and pegylated alpha interferon (“Peg-IFN”), the commonly used treatment regimen in the indication.

Published
08 November 2011
From
Transgene press release
New and experimental hepatitis C treatment
All-Oral Treatment Regimen of Bristol-Myers Squibb’s Investigational NS5A and NS3 Inhibitors Achieved 90% Sustained Virologic Response (SVR12) in Phase II Study Sentinel Cohort of Genotype 1b Null Responders

Results add to data suggesting that SVR can be achieved with the combination of daclatasvir (BMS-790052) and asunaprevir (BMS-650032) in HCV genotype 1b patients; study expanded to include alfa/RBV ineligible or intolerant patients

Published
08 November 2011
From
Bristol-Myers Squibb press release
New and experimental hepatitis C treatment
Interferon-free combination of BI 201335 plus BI 207127 and ribavirin shows up to 76% of patients achieve a virological response at week 12, and 59% achieve SVR12 with 16 weeks treatment

Boehringer Ingelheim today announced results from a pre-specified interim analysis of a Phase IIb study, named SOUND-C2. These data showed the combination of two oral direct acting anti hepatitis C virus (HCV) compounds (the protease inhibitor BI 201335 and the polymerase inhibitor BI 207127, with and without ribavirin (RBV), was successful in providing virological response rates at week 12 in treatment-naïve patients infected with the most difficult to treat genotype-1 (GT1) HCV.

Published
08 November 2011
From
Boehringer Ingelheim press release
New and experimental hepatitis C treatment
Positive Interim Data From a Phase 2 Study of INCIVEK(TM) (telaprevir) Combination Therapy in People Co-Infected with Hepatitis C and HIV Presented at The Liver Meeting(R)

Data showed 74% of people had undetectable hepatitis C virus 24 weeks after starting INCIVEK combination treatment; Vertex to initiate Phase 3 study to evaluate 24- and 48-week treatment durations in people who are co-infected.

Published
07 November 2011
From
Vertex (press release)
New and experimental hepatitis C treatment
Novartis DEB025 data showed viral clearance as early as six weeks and potential for interferon-free therapy in hepatitis C patients

Novartis announced today new Phase II data showing that first-in-class DEB025 (alisporivir) may produce early viral elimination (or clearance) in interferon-free regimens (as monotherapy or with ribavirin), in previously untreated patients infected with the hepatitis C virus (HCV) genotypes 2 and 3.

Published
07 November 2011
From
Novartis (press release)
New and experimental hepatitis C treatment
Twelve Weeks Interferon-Free PSI-7977 Regimen Cures 100 Percent Hep C Genotype 2/3

A twelve-week course of Pharmasset’s once-daily experimental nucleotide analog PSI-7977, combined with ribavirin, cured 10 of 10 people living with genotype 2/3 hepatitis C virus (HCV) who used the regimen—without pegylated interferon—in a Phase II clinical trial. The highly encouraging results were reported Sunday, November 6, at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco.

Published
06 November 2011
From
AIDSMeds
New and experimental hepatitis C treatment
Copy of Twelve Weeks Interferon-Free PSI-7977 Regimen Cures 100 Percent Hep C Genotype 2/3

A twelve-week course of Pharmasset’s once-daily experimental nucleotide analog PSI-7977, combined with ribavirin, cured 10 of 10 people living with genotype 2/3 hepatitis C virus (HCV) who used the regimen—without pegylated interferon—in a Phase II clinical trial. The highly encouraging results were reported Sunday, November 6, at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco.

Published
06 November 2011
From
Kaiser Daily Global Health Policy Report
New and experimental hepatitis C treatment
AASLD-Santaris Phase 2a Data of Miravirsen Shows Dose-Dependent, Prolonged Viral Reduction of 2-3 Logs HCV RNA After Four-Week

New clinical data from the Phase 2a study demonstrate that four out of nine patients treated at the highest dose (7 mg/kg) with miravirsen became HCV RNA undetectable with just four weeks of dosing. These data provide clinical evidence that miravirsen's unique mechanism-of-action offers high barrier to viral resistance and the potential for cure with monotherapy.

Published
05 November 2011
From
Santaris press release
← Prev1...2122232425...32Next →

Filter by country